| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | -0.84% | Morgan Stanley | $40 → $40 | Reiterates | Equal-Weight → Equal-Weight |
| 05/25/2023 | 23.95% | Oppenheimer | → $50 | Reiterates | Outperform → Outperform |
| 02/23/2023 | -0.84% | Morgan Stanley | $34 → $40 | Maintains | Equal-Weight |
| 02/17/2023 | 18.99% | Citigroup | $41 → $48 | Maintains | Buy |
| 02/16/2023 | 23.95% | Oppenheimer | → $50 | Upgrades | Perform → Outperform |
| 02/16/2023 | 14.03% | Wells Fargo | $41 → $46 | Maintains | Overweight |
| 02/16/2023 | 14.03% | Fermium Research | $38 → $46 | Reiterates | → Buy |
| 01/09/2023 | 1.64% | Wells Fargo | $33 → $41 | Maintains | Overweight |
| 12/15/2022 | 1.64% | Citigroup | $32 → $41 | Maintains | Buy |
| 11/07/2022 | -15.72% | Morgan Stanley | $37 → $34 | Maintains | Equal-Weight |
| 10/25/2022 | -8.28% | Morgan Stanley | $50 → $37 | Maintains | Equal-Weight |
| 10/17/2022 | -0.84% | Deutsche Bank | → $40 | Initiates Coverage On | → Buy |
| 09/29/2022 | -5.8% | Wells Fargo | $53 → $38 | Maintains | Overweight |
| 09/28/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 07/28/2022 | 23.95% | Morgan Stanley | $63 → $50 | Maintains | Equal-Weight |
| 07/27/2022 | 38.82% | Baird | $63 → $56 | Maintains | Outperform |
| 07/07/2022 | 31.38% | Wells Fargo | $65 → $53 | Maintains | Overweight |
| 06/28/2022 | 26.43% | Jefferies | $67 → $51 | Maintains | Buy |
| 04/21/2022 | 61.13% | Wells Fargo | $60 → $65 | Maintains | Overweight |
| 04/18/2022 | 48.74% | Wells Fargo | $65 → $60 | Maintains | Overweight |
| 01/11/2022 | 56.17% | Morgan Stanley | $57 → $63 | Maintains | Equal-Weight |
| 12/10/2021 | 61.13% | Wells Fargo | $62 → $65 | Maintains | Overweight |
| 05/12/2021 | 41.3% | Morgan Stanley | $45 → $57 | Maintains | Equal-Weight |
| 02/11/2021 | 11.55% | Morgan Stanley | $42 → $45 | Maintains | Equal-Weight |
| 01/07/2021 | 38.82% | Jefferies | $41 → $56 | Upgrades | Hold → Buy |
| 01/06/2021 | — | Citigroup | Upgrades | Neutral → Buy | |
| 12/14/2020 | 4.12% | Morgan Stanley | $37 → $42 | Downgrades | Overweight → Equal-Weight |
| 10/14/2020 | -8.28% | Morgan Stanley | $30 → $37 | Maintains | Overweight |
| 10/02/2020 | -3.32% | Goldman Sachs | → $39 | Upgrades | Neutral → Buy |
| 09/25/2020 | -13.24% | Wells Fargo | $33 → $35 | Maintains | Overweight |
| 09/04/2020 | -25.63% | Citigroup | → $30 | Initiates Coverage On | → Neutral |
What is the target price for Avient (AVNT)?
The latest price target for Avient (NYSE: AVNT) was reported by Morgan Stanley on August 1, 2023. The analyst firm set a price target for $40.00 expecting AVNT to fall to within 12 months (a possible -0.84% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avient (AVNT)?
The latest analyst rating for Avient (NYSE: AVNT) was provided by Morgan Stanley, and Avient reiterated their equal-weight rating.
When is the next analyst rating going to be posted or updated for Avient (AVNT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avient, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avient was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
Is the Analyst Rating Avient (AVNT) correct?
While ratings are subjective and will change, the latest Avient (AVNT) rating was a reiterated with a price target of $40.00 to $40.00. The current price Avient (AVNT) is trading at is $40.34, which is out of the analyst's predicted range.